Allmed Cost Of Revenue from 2010 to 2025

002950 Stock   9.15  0.24  2.56%   
Allmed Medical's Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Cost Of Revenue is expected to dwindle to about 1.9 B. From 2010 to 2025 Allmed Medical Cost Of Revenue quarterly data regression line had arithmetic mean of  1,524,163,909 and r-squared of  0.72. View All Fundamentals
 
Cost Of Revenue  
First Reported
2019-03-31
Previous Quarter
594.3 M
Current Value
638.5 M
Quarterly Volatility
138.8 M
 
Covid
Check Allmed Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allmed Medical's main balance sheet or income statement drivers, such as Tax Provision of 84.1 M, Interest Income of 2.5 M or Interest Expense of 24.1 M, as well as many indicators such as . Allmed financial statements analysis is a perfect complement when working with Allmed Medical Valuation or Volatility modules.
  
This module can also supplement various Allmed Medical Technical models . Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Allmed Stock

Allmed Medical financial ratios help investors to determine whether Allmed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Allmed with respect to the benefits of owning Allmed Medical security.